/images/ppid_59c68470-image-177945004294069714.webp)
/images/ppid_59c68470-image-177986502818242679.webp)
What is the story about?
Shares of Shilpa Medicare Ltd surged about 9% after the company reported a sharp jump in the March quarter profit, aided by strong operating performance and exceptional gains during the quarter.
The company reported consolidated net profit of ₹108 crore for Q4FY26, compared to ₹14.5 crore in the year-ago quarter. Revenue from operations rose 32% year-on-year to ₹437 crore from ₹331 crore, while Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) increased 49.6% to ₹119.7 crore from ₹80 crore a year earlier. EBITDA margin expanded to 27.4% from 24.1%.
Profitability during the quarter was also supported by exceptional gains. Shilpa Medicare reported a net exceptional gain of around ₹25 crore in Q4FY26, compared to an exceptional loss of ₹30.6 crore in the year-ago period.
Also read: Sun Pharma Q4 Results: Drugmaker shares fall after earnings miss; US sales at $459 million
The company recorded a provision write-back and gains related to investments during the quarter, while the previous year included impairment charges and losses linked to investments and settlement-related provisions.
For FY26, consolidated revenue rose to ₹1,577 crore from ₹1,074 crore in FY25, while net profit increased sharply to ₹84.9 crore from ₹7.8 crore a year ago. EBITDA for the year stood at ₹358.5 crore compared to ₹195.6 crore in FY25, with margin improving to 22.7% from 18.2%.
The board recommended a final dividend of ₹0.60 per equity share for FY26, subject to shareholder approval.
Separately, the company approved shifting its registered office from Karnataka to Maharashtra, subject to regulatory and shareholder approvals.
Shilpa Medicare also said its wholly owned subsidiaries will invest ₹4.44 crore for a 28% equity stake in Neo Green Power Project Pvt. Ltd. to meet captive renewable energy requirements.
Shares of the company rose about 9% on Q4 results, hitting an intraday high of ₹518.55, but gave up most of the gains and were trading at ₹481.45 as of 3.21 pm, just 1.43% baove Thursday's closing price. The stock has gained 18% in the last month and about 31% over the past 12 months.
The company reported consolidated net profit of ₹108 crore for Q4FY26, compared to ₹14.5 crore in the year-ago quarter. Revenue from operations rose 32% year-on-year to ₹437 crore from ₹331 crore, while Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) increased 49.6% to ₹119.7 crore from ₹80 crore a year earlier. EBITDA margin expanded to 27.4% from 24.1%.
Profitability during the quarter was also supported by exceptional gains. Shilpa Medicare reported a net exceptional gain of around ₹25 crore in Q4FY26, compared to an exceptional loss of ₹30.6 crore in the year-ago period.
Also read: Sun Pharma Q4 Results: Drugmaker shares fall after earnings miss; US sales at $459 million
The company recorded a provision write-back and gains related to investments during the quarter, while the previous year included impairment charges and losses linked to investments and settlement-related provisions.
For FY26, consolidated revenue rose to ₹1,577 crore from ₹1,074 crore in FY25, while net profit increased sharply to ₹84.9 crore from ₹7.8 crore a year ago. EBITDA for the year stood at ₹358.5 crore compared to ₹195.6 crore in FY25, with margin improving to 22.7% from 18.2%.
The board recommended a final dividend of ₹0.60 per equity share for FY26, subject to shareholder approval.
Separately, the company approved shifting its registered office from Karnataka to Maharashtra, subject to regulatory and shareholder approvals.
Shilpa Medicare also said its wholly owned subsidiaries will invest ₹4.44 crore for a 28% equity stake in Neo Green Power Project Pvt. Ltd. to meet captive renewable energy requirements.
Shares of the company rose about 9% on Q4 results, hitting an intraday high of ₹518.55, but gave up most of the gains and were trading at ₹481.45 as of 3.21 pm, just 1.43% baove Thursday's closing price. The stock has gained 18% in the last month and about 31% over the past 12 months.
/images/ppid_a911dc6a-image-177986552841046648.webp)
/images/ppid_59c68470-image-177986517703646564.webp)
/images/ppid_59c68470-image-177986509475962748.webp)
/images/ppid_59c68470-image-177986513348789047.webp)
/images/ppid_59c68470-image-177986504467881367.webp)
/images/ppid_59c68470-image-177986506479671391.webp)
/images/ppid_59c68470-image-177986510530841232.webp)